ARKG is trading at $48.02, down 3.01%, amid concerns about healthcare oversight and drug-pricing policy that may weigh on biotech sentiment. - Democrats’ midterm sweep raised these concerns, but analysts described the near-term policy impact as uncertain. - Despite ARKG’s decline, XLV was up 2.6% and IBB 2.9% premarket; major indexes were higher, so broad-market weakness does not explain the drop.